Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

A Study of Pegylated Liposomal Doxorubicin and Cyclophosphamide in Her2-negative Stage I and II Breast Cancer Patients

This study is currently recruiting participants. (see Contacts and Locations)
Verified February 2017 by TTY Biopharm
Sponsor:
Information provided by (Responsible Party):
TTY Biopharm
ClinicalTrials.gov Identifier:
NCT01210768
First received: August 31, 2010
Last updated: February 6, 2017
Last verified: February 2017
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: August 2018
  Estimated Primary Completion Date: July 2018 (Final data collection date for primary outcome measure)